Shoulder Innovations, Inc. (NYSE: SI), a cultivate(MD) portfolio company reported financial results for the fourth quarter and full year ended December 31, 2025.
Financial Highlights
- Generated net revenue of $14.4 million in the fourth quarter, a 65% increase over the prior year quarter
- Generated net revenue of $47.3 million for the full year, a 50% increase over the prior year
- Achieved gross margin of 76.7% for the fourth quarter and 76.5% for the full year
- Initiating full year 2026 net revenue guidance of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue
Full Year and Recent Business Highlights
- Sold 1,976 total implant systems in the fourth quarter, a 62% increase over the prior year quarter
- Ended 2025 with 134 core surgeons and contender surgeons, a 61% increase over the prior year
- Commenced limited user release of the InSet™ I-135RFX Humeral Stem for primary, revision, and certain fracture indications of the humeral head
- Commenced limited user release of the N-22 Humeral Head for patients with metal hypersensitivity
- Appointed Drew Hykes, former CEO of Inari Medical, to Board of Directors
- Announced a strategic partnership with Interventional Systems to introduce a robotic platform for shoulder arthroplasty
“2025 was a transformational year for Shoulder Innovations. We continued to add new surgeon customers at an accelerated pace, drove rapid commercial adoption of our advanced implant systems, and solidified our position as an innovation leader in the shoulder space, all while beginning our journey as a public company,” said Rob Ball, CEO of Shoulder Innovations. “These efforts culminated in record full-year net revenue of $47.3 million, representing an exceptional 50% increase year-over-year, supported by accelerating growth in the second half of the year.”
Mr. Ball continued, “Looking into 2026, our momentum remains strong. Our key strategic priorities are focused on delivering sustained growth through world class execution and innovation. With a growing product portfolio, a comprehensive enabling technology strategy, our expanding commercial talent, and a strong balance sheet, we believe we are well positioned to further extend and strengthen our leadership position in shoulder surgical care in the years ahead.
